{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:06:18Z","timestamp":1789833978838,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.vhri.2026.101675","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:14:18Z","timestamp":1784261658000},"page":"101675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hospital Budget Impact and Provider-Side Economic Evaluation of Lecanemab and Donanemab Under Japan\u2019s National Fee Schedule: A Head-to-Head Linear Model"],"prefix":"10.1016","volume":"57","author":[{"given":"Kotaro","family":"Makita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Arakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Ohida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Kutsuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2026.101675_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vhri.2026.101675_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.vhri.2026.101675_bib3","series-title":"Appropriate Use Promotion Guideline: Lecanemab (Genetical Recombination) (in Japanese)","year":"2023"},{"key":"10.1016\/j.vhri.2026.101675_bib4","series-title":"Appropriate Use Promotion Guideline: Donanemab (Genetical Recombination) (in Japanese)","year":"2024"},{"issue":"5","key":"10.1016\/j.vhri.2026.101675_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.vhri.2026.101675_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jalz.2017.12.006","article-title":"The cost of Alzheimer\u2019s disease in China and re-estimation of costs worldwide","volume":"14","author":"Jia","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.vhri.2026.101675_bib8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jalz.2014.10.005","article-title":"Hospital admissions, outpatient visits and healthcare costs of community-dwellers with Alzheimer\u2019s disease","volume":"11","author":"Tolppanen","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.vhri.2026.101675_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1403494815614705","article-title":"Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer\u2019s disease in a Finnish nationwide cohort","volume":"44","author":"Taipale","year":"2016","journal-title":"Scand J Public Health"},{"issue":"5-6","key":"10.1016\/j.vhri.2026.101675_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/07853890.2019.1642507","article-title":"Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer\u2019s disease","volume":"51","author":"Kalam\u00e4gi","year":"2019","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.vhri.2026.101675_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.13931","article-title":"Economic burden of Alzheimer disease and related dementias by race and ethnicity, 2020 to 2060","volume":"8","author":"Mudrazija","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vhri.2026.101675_bib12","article-title":"Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer\u2019s disease treatment","volume":"13","author":"Lam","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"10.1016\/j.vhri.2026.101675_bib13","article-title":"Long-term cost-effectiveness of a more accurate diagnostic work-up for dementia","volume":"17","author":"van der Veere","year":"2025","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"10.1016\/j.vhri.2026.101675_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2191-1991-2-18","article-title":"Methodological considerations in cost of illness studies on Alzheimer disease","volume":"2","author":"Costa","year":"2012","journal-title":"Health Econ Rev"},{"key":"10.1016\/j.vhri.2026.101675_bib15","series-title":"Overview and Basic Concept of the DPC\/PDPS System (in Japanese)","year":"2010"},{"key":"10.1016\/j.vhri.2026.101675_bib16","series-title":"FY2024 Revision of Medical Fees: Inpatient V (DPC\/PDPS & Short-Stay)","year":"2024"},{"key":"10.1016\/j.vhri.2026.101675_bib17","series-title":"Price Adjustment for Leqembi Based on Cost-Effectiveness Evaluation","year":"2025"},{"issue":"3","key":"10.1016\/j.vhri.2026.101675_bib19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.vhri.2026.101675_bib20","series-title":"Iry\u014d no Sh\u014dhizei (Consumption Tax in Medical Care: Non-taxable Supply; Reimbursement\/Price Add-Ons for Non-deductible VAT) (in Japanese)","year":"2024"},{"issue":"3","key":"10.1016\/j.vhri.2026.101675_bib26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hec.3613","article-title":"Estimating the opportunity costs of bed-days","volume":"27","author":"Sandmann","year":"2018","journal-title":"Health Econ"},{"key":"10.1016\/j.vhri.2026.101675_bib27","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"issue":"11","key":"10.1016\/j.vhri.2026.101675_bib35","first-page":"131","article-title":"Time-driven activity-based costing","volume":"82","author":"Kaplan","year":"2004","journal-title":"Harv Bus Rev"},{"issue":"9","key":"10.1016\/j.vhri.2026.101675_bib36","first-page":"46","article-title":"How to solve the cost crisis in health care","volume":"89","author":"Kaplan","year":"2011","journal-title":"Harv Bus Rev"},{"issue":"7","key":"10.1016\/j.vhri.2026.101675_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.healthpol.2017.04.013","article-title":"Time-driven activity-based costing in health care: a systematic review of the literature","volume":"121","author":"Keel","year":"2017","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"key":"10.1016\/j.vhri.2026.101675_bib38","series-title":"Standard Language Test of Aphasia (SLTA) Manual (in Japanese)","year":"2003"},{"key":"10.1016\/j.vhri.2026.101675_bib39","author":"Shuppansha"},{"issue":"5","key":"10.1016\/j.vhri.2026.101675_bib40","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/2014.8.FOCUS14381","article-title":"Time-driven activity-based costing: a driver for provider engagement in costing activities and redesign initiatives","volume":"37","author":"McLaughlin","year":"2014","journal-title":"Neurosurg Focus"},{"issue":"6","key":"10.1016\/j.vhri.2026.101675_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032573","article-title":"Time-driven activity-based costing for patients with multiple chronic conditions: a mixed-method study to cost care in a multidisciplinary and integrated care delivery centre at a university-affiliated tertiary teaching hospital in Stockholm, Sweden","volume":"10","author":"Keel","year":"2020","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.vhri.2026.101675_bib42","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jval.2024.11.003","article-title":"The application of time-driven activity-based costing in oncology: a systematic review","volume":"28","author":"Busschaert","year":"2025","journal-title":"Value Health"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:55:10Z","timestamp":1789833310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":28,"alternative-id":["S2212109926000907"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101675","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hospital Budget Impact and Provider-Side Economic Evaluation of Lecanemab and Donanemab Under Japan\u2019s National Fee Schedule: A Head-to-Head Linear Model","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101675"}}